ASBP
Aspire Biopharma Holdings, Inc.
There isn't enough reported data to score ASBP yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ASBP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Strong |
ASBP's balance sheet is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its revenue.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ASBP PE Valuation
ASBP has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ASBP Forward outlook
There aren't enough analyst estimates for ASBP to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ASBP Earnings Per Share
ASBP and HIMS do not have enough comparable growth data to identify a winner.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ASBP Quarterly Revenue
ASBP's revenue has grown year over year for four quarters in a row: $63,104 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -4244% | N/A |
| Q1 2026 | -5806% | N/A |
| Q4 2025 | -43404% | N/A |
| Q3 2025 | -59016% | N/A |
HIMS has the edge over ASBP on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ASBP on profitability, with a higher operating margin.
ASBP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.1M | -$975.4K |
| Q1 2026 | -$3M | -$1.3M |
| Q4 2025 | -$927.8K | -220% |
| Q2 2025 | -$1.1M | -$548K |
| Q1 2025 | -$1.8M | +$508.5K |
| Q4 2024 | $772.1K | +$928.3K |
| Q2 2024 | -$592.3K | -$402.4K |
| Q1 2024 | -$2.3M | -$2.1M |
ASBP has burned cash in almost every quarter: −$7M over the past year, against −$3M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ASBP on cash generation, producing positive trailing cash flow while its opponent burns cash.
ASBP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2415% | +997K shares |
| 1 year | +2447% | +997K shares |
ASBP has 1M diluted shares, up 2447% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q2 2024 | $13.8M |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | $632,968 |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ASBP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ASBP Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | 0.0x | Very low |
| Q3 2023 | -0.0x | Very low |
| Q2 2023 | -0.1x | Net Cash |
| Q1 2023 | -0.2x | Net Cash |
ASBP's net debt is less than a year of its operating earnings (EBITDA).
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ASBP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.4 | Oversold |
| Stochastic | 60.1 | Neutral |
ASBP's weekly RSI is 25 (oversold) and its Stochastic is 60 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ASBP PE vs Healthcare Sector
ASBP has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ASBP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.45 | 0.6% below |
| 20 week MA | $7.92 | 6.1% above |
| 50 week MA | $30.4 | 72% below |
| 100 week MA | $1,485.1 | 99% below |
| 200 week MA | $7,335.9 | 100% below |
ASBP has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ASBP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $12,000.0 | $12,372.0 | +3.1% |
| 2023 | $12,372.0 | $13,068.0 | +5.6% |
| 2024 | $13,068.0 | $13,800.0 | +5.6% |
| 2025 | $13,800.0 | $129.6 | -99% |
| 2026 YTD | $129.6 | $8.40 | -94% |
ASBP is down 94% so far in 2026, after finishing higher in three of the previous four years.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over ASBP on returns for 2026, with the stronger performance.